ArticleLeukemia2020
Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Monocyte Galectin-9 is associated with CD8⁺ T-cell dysfunction and early relapse after haploidentical hematopoietic stem cell transplantation.Biomarker research · 2026Article
- Longitudinal TCR repertoire profiling predicts refractory cytomegalovirus reactivation after haploidentical hematopoietic stem cell transplantation.Virology journal · 2026Article
- Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients - PART 1: Risk Factors, Clinical Impact and Immune Response.Reviews in medical virology · 2026Review
- Quantitative evaluation of T-cell repertoire restoration following hematopoietic stem cell transplantation in patients with and without graft versus host disease.Frontiers in immunology · 2026Article
- T cell and monocyte activation in concert with hematopoietic stem cell interactions shapes the post-allogeneic transplant immune landscape in poor graft function.Frontiers in immunology · 2026Article
- T Cell immune reconstitution after allo-HSCT: key factors and implications.Blood science (Baltimore, Md.) · 2025Review
- Understanding Telomere Biology in Hematopoietic Cell Transplantation: A Dynamical Systems Perspective.Transplantation and cellular therapy · 2025Article
- A High-Throughput Sequencing Strategy for Clinical Repertoire Profiling of T Cell Receptor Beta Chain: Development and Reference Values Across Healthy Adults, Paediatrics, and Cord Blood Units.International journal of molecular sciences · 2025Article
- Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.medRxiv : the preprint server for health sciences · 2025Article
- NK- and T-cell repertoire is established early after allogeneic HSCT and is imprinted by CMV reactivation.Blood advances · 2024Article
- Insights into cytomegalovirus-associated T cell receptors in recipients following allogeneic hematopoietic stem cell transplantation.Virology journal · 2024Article
- Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse.Science translational medicine · 2023Article
- Prospects of Cytomegalovirus-Specific T-Cell Receptors in Clinical Diagnosis and Therapy.Viruses · 2023Review
- CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation.Leukemia · 2023Article
- Two types of human TCR differentially regulate reactivity to self and non-self antigens.iScience · 2022Article
- Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?Cancers · 2022Review
- Features of repertoire diversity and gene expression in human cytotoxic T cells following allogeneic hematopoietic cell transplantation.Communications biology · 2021Article
- T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection.Bone marrow transplantation · 2021Article
- Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation.JCI insight · 2021Article
- CDR3 and V genes show distinct reconstitution patterns in T cell repertoire post-allogeneic bone marrow transplantation.Immunogenetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After allogeneic hematopoietic stem cell transplantation (HSCT), immune reconstitution leads to the development of a new T-cell repertoire. Immune reconstitution could be influenced by events such as conditioning, infections, and graft versus host disease (GVHD). Factors influencing the TCR diversity are of great interest to fine-tune the strategy for donor selection and to optimize standard of care. In this work, immunosequencing of the TCR CDR3β region was carried out in a large cohort of 116 full chimeric recipients at 1 year post-HSCT and their respective donors prior to transplantation. The repertoire overlap before and after HSCT was minimal, supporting de novo reconstitution as a primary pathway at any age. Among the parameters investigated, increased patient and/or donor age as well as positive CMV serologic status reinforced by CMV infection/reactivation were the ones significantly associated with a reduced diversity at 1 year post-HSCT. CMV-specific T-cell clones were shown to influence the clonality of the repertoire alongside the expansion of limited numbers of non-CMV T-cell populations. Interestingly, at the exception of CMV infection/reactivation, TCR diversity was not predictive of GVHD, relapse, death, or infections post-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.